Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Lee, Myung Ah | - |
dc.contributor.author | Ahn, Myung Ju | - |
dc.contributor.author | Kim, Hoon-Kyo | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Lee, Nam Su | - |
dc.contributor.author | Park, Byung Joo | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.date.accessioned | 2021-09-09T13:12:49Z | - |
dc.date.available | 2021-09-09T13:12:49Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2008-01 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/124545 | - |
dc.description.abstract | Objectives The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. Methods The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion followed by gemcitabine 1,250 mg/m(2) in 30-min intravenous infusion on days 1 and 8, repeated every 3 weeks until disease progression, unacceptable toxicity, patient's refusal or up to 8 cycles. Results Thirty-nine patients with advanced biliary cancer were enrolled between March 2003 and August 2003. Fourteen patients (40%) had gall bladder cancer and 20 patients (57%) had cholangiocarcinoma. Thirty-two patients (91%) had metastatic disease at study entry with liver being the most commonly involved site of metastasis. About 84.5 and 94.2% of the initially planned dose were administered for gemcitabine and cisplatin, respectively. In the ITT population (n = 35), six partial responses were observed for an objective response rate of 17.1% (95% CI; 4.7-29.6%). Ten patients (28.6%) had stable disease, 16 (45.7%) progressed, and three (8.6%) were not evaluable. For the 35 patients in the ITT population, the median overall survival time was 8.6 months (95% CI; 6.1-10.4 months). The median time to disease progression was 3.2 months (95% CI; 2.3-4.9 months) and the median time to treatment failure was 3.1 months (95% CI; 1.9-4.1 months). Among the six tumor responders, the median duration of tumor response was 7.3 months (95% CI; 5.6-11.0 months). The most common grade 3/4 maximum toxicities were nausea (3.4%) and vomiting (2.7%). Conclusion The combination chemotherapy with gemcitabine and cisplatin in this trial demonstrated moderate antitumor activity with favorable toxicity profile. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | IN-VITRO | - |
dc.subject | CANCER | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | CAPECITABINE | - |
dc.subject | GALLBLADDER | - |
dc.subject | COMBINATION | - |
dc.subject | EXPERIENCE | - |
dc.title | Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.identifier.doi | 10.1007/s00280-007-0444-5 | - |
dc.identifier.scopusid | 2-s2.0-34848831495 | - |
dc.identifier.wosid | 000249916800006 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.61, no.1, pp.47 - 52 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 61 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 47 | - |
dc.citation.endPage | 52 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | GALLBLADDER | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordAuthor | biliary tract cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.